

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Thursday 26th September 2024. I am pleased to confirm the following.

How many newly diagnosed patients with chronic lymphocytic leukaemia (CLL) have started first-line treatment in your Trust or Centre during the 6-month period February 2024 to July 2024?

Answer:6

How many of these newly diagnosed patients with CLL received chemoimmunotherapy (CIT) as first-line treatment?

CITs include fludarabine + cyclophosphamide + rituximab (FCR), fludarabine + rituximab (FR), bendamustine + rituximab (BR), bendamustine monotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), obinutuzumab ± chlorambucil, rituximab + chlorambucil and ofatumumab

Answer: 0

Please complete the table below with how many newly diagnosed patients with CLL have started first-line treatment with each of the following CITs during the 6-month period February 2024 to July 2024

- FCR (fludarabine + cyclophosphamide + rituximab)
- FR (fludarabine + rituximab)
- BR (bendamustine + rituximab)
- Bendamustine monotherapy
- RCHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)
- Obinutuzumab ± chlorambucil
- Rituximab + chlorambucil
- Ofatumumab
- Other – please specify

Note: this should only include newly diagnosed patients with CLL who have started first-line treatment during the 6-month window

Answer:

Treatment option	Number of newly diagnosed patients with CLL starting first line treatment during the 6-month period February 2024 to July 2024
FCR	0
FR	0
BR	0
Bendamustine monotherapy	0
R-CHOP	0
Obinutuzumab ± chlorambucil	0
Rituximab + chlorambucil	0
Chlorambucil monotherapy	0
Rituximab monotherapy	0
Ofatumumab	0
Other – please specify	<i>acalabrutinib and Venetoclax-Rituximab</i>

Please be advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Information Governance Administrator
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the
'Re-use of Public Sector Information Regulations' and best practice.